Sun Pharma#39;s specialty product Ilumetri included in China#39;s national reimbursement drug list on December 13, 2023 at 8:50 am

Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.